Cargando…

The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment

G protein-coupled Receptor Kinase 6 (GRK6) belongs to a family of kinases that phosphorylate GPCRs. GRK6 levels were found to be altered in Parkinson's Disease (PD) and D(2) dopamine receptors are supersensitive in mice lacking GRK6 (GRK6-KO mice). To understand how GRK6 modulates the behaviora...

Descripción completa

Detalles Bibliográficos
Autores principales:	Managò, Francesca, Espinoza, Stefano, Salahpour, Ali, Sotnikova, Tatyana D., Caron, Marc G., Premont, Richard T., Gainetdinov, Raul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293148/ https://www.ncbi.nlm.nih.gov/pubmed/22393477 http://dx.doi.org/10.1038/srep00301

Ejemplares similares

The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
por: Sotnikova, Tatyana D., et al.
Publicado: (2010)

Correction: The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
por: Sotnikova, Tatyana D., et al.
Publicado: (2010)

Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON l-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease
por: Vinuela, A., et al.
Publicado: (2008)

GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson’s disease via its RGS homology domain
por: Ahmed, Mohamed R., et al.
Publicado: (2015)

Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease
por: Sotnikova, Tatyana D, et al.
Publicado: (2005)

BRET biosensors to study GPCR biology, pharmacology, and signal transduction
por: Salahpour, Ali, et al.
Publicado: (2012)

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
por: Espinoza, Stefano, et al.
Publicado: (2018)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

Enhanced Dopamine Transmission and Hyperactivity in the Dopamine Transporter Heterozygous Mice Lacking the D3 Dopamine Receptor
por: Sotnikova, Tatyana D., et al.
Publicado: (2020)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

GRK5 – A Functional Bridge Between Cardiovascular and Neurodegenerative Disorders
por: Hendrickx, Jhana O., et al.
Publicado: (2018)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
Publicado: (2017)

L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

Striatal Glutamate Release in l-DOPA-Induced Dyskinetic Animals
por: Nevalainen, Nina, et al.
Publicado: (2013)

Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication
por: Festini, Sara B., et al.
Publicado: (2015)

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
por: Hoon, Monique, et al.
Publicado: (2017)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
por: Bello, Fabio Del, et al.
Publicado: (2019)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974)

GRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability
por: He, Minchao, et al.
Publicado: (2016)

Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson’s Disease Therapy
por: Sukhanov, Ilya, et al.
Publicado: (2022)

Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
por: Shin, Keon Sung, et al.
Publicado: (2015)

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson’s Disease
por: Peña, Edgar, et al.
Publicado: (2021)

Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors
por: Beaulieu, Jean-Martin, et al.
Publicado: (2011)

Effect of the 5-HT(4) receptor agonist tegaserod on the expression of GRK2 and GRK6 in the rat gastrointestinal tract
por: Nedi, Teshome, et al.
Publicado: (2018)

Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson’s disease
por: Wiesen, Tom, et al.
Publicado: (2022)

L-Dopa and the Albino Riddle: Content of L-Dopa in the Developing Retina of Pigmented and Albino Mice
por: Roffler-Tarlov, Suzanne, et al.
Publicado: (2013)

β-Lapachone ameliorates L-DOPA-induced dyskinesia in a 6-OHDA-induced mouse model of Parkinson's disease
por: Ryu, Young-Kyoung, et al.
Publicado: (2021)

Trafficking GRK2: Cellular and Metabolic consequences of GRK2 subcellular localization.
por: Sorriento, Daniela, et al.
Publicado: (2014)

Suitability of GRK Antibodies for Individual Detection and Quantification of GRK Isoforms in Western Blots
por: Reichel, Mona, et al.
Publicado: (2022)

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
por: Comi, Cristoforo, et al.
Publicado: (2017)

L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients
por: Cao, Chunyan, et al.
Publicado: (2020)

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
por: Goshima, Yoshio, et al.
Publicado: (2019)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
por: Lanza, Kathryn, et al.
Publicado: (2021)

Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia
por: Shimada, Tomoyo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9f4kabk3oroq1jp6g8gq70ge58